TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a...
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose...
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose...
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose...
KVA12123 Clears Cohorts in Monotherapy in the Phase 1/2 VISTA-101 Trial
Kineta Announces Restructuring and Exploration of Strategic Alternatives
In 2022, Kineta swooped in to rescue Yumanity’s immunotherapy from the scrapheap. Now, Kineta needs some rescuing itself.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...